Notable Labs to Present Results from Clinical Platform Validation Study at the 2023 American Association for Cancer Research (AACR) Annual Meeting
FOSTER CITY, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced that results from a clinical validation study of its Predictive Precision Medicine Platform (PPMP) will be presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida on April 14-19, 2023.
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. The meeting highlights the work of the best minds in cancer research from institutions all over the world.
The full texts of the published abstracts can be found on the AACR Annual Meeting website.
Details on the corresponding posters are shown below.
Abstract title: Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes
Abstract Number: 4342
Session Category: Clinical Research Excluding Trials
Session Title: Biomarkrs and Therapeutic Benefit 4
Time: April 18, 2023, 9:00 AM-12:30 PM ET
Additional meeting information can be found on the AACR website, https://www.aacr.org. The poster will be available under Publications section- Scientific Posters on the Company’s website shortly after the event.
About Notable Labs, Inc.
Notable Labs, Inc. is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (“PPMP”), Notable bio-simulates a cancer treatment and predicts whether or not a patient is likely to respond to that specific therapeutic. Notable’s PPMP can identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. By continually advancing and expanding the reach of the PPMP across diseases and predicted medical outcomes, Notable aims to be the leader in precision medicine and revolutionize the way in which patients seek and receive treatments that work best for them – patient by patient and cancer by cancer.
Notable believes it has created a targeted and de-risked in-licensing strategy to deliver a product’s medical impact and commercial value faster, higher, and with a greater likelihood of success than traditional drug development. By transforming historical standards of care, Notable aims to create dramatic positive impact for patients and the healthcare community. Notable is headquartered in Foster City, California. Learn more at www.notablelabs.com and follow us @notablelabs.
Investor Relations: Daniel Ferry, LifeSci Advisors
+1 (617) 430-7576, [email protected]